Eli Lilly and Company announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly,...
New data released from KEYNOTE-021, Cohort G, which evaluated Alimta (pemetrexed), from Eli Lilly, plus carboplatin in combination with Merck's...
Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an...
NICE (The National Institute of Health and Clinical Excellence) has not recommended Alimta (pemetrexed) from Eli Lilly for use as...
Results from the PRONOUNCE trial of Alimta (pemetrexed for injection), from Eli Lilly, for treatment of nonsquamous Non-Small Cell Lung...
Innovent Biologics and Eli Lilly and Company announced that the FDA accepted for review a Biologics License Application (BLA) for Tyvyt (sintilimab injection) in combination with Alimta (pemetrexed) and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC).
Eli Lilly and Company announced that the FDA has granted approval for a new indication for Alimta (pemetrexed for injection)...
Merck Inc. has announced that the FDA has approved Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, in combination with pemetrexed (brand...
The FDA has announced that patients may receive Alimta (pemetrexed for injection), from Eli Lilly, as a maintenance therapy following...